会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
    • 磺酰苯化合物作为抗炎/止痛剂
    • US06727238B2
    • 2004-04-27
    • US10465767
    • 2003-06-18
    • Kazuo AndoTomoki KatoAkiyoshi KawaiTomomi Nonomura
    • Kazuo AndoTomoki KatoAkiyoshi KawaiTomomi Nonomura
    • A61K3133
    • A61K31/422A61K31/427A61K31/454C07C311/39C07C317/36C07D207/325C07D207/333C07D401/10C07D403/10C07D405/10C07D409/10C07D413/10C07D417/10
    • This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo,, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
    • 本发明提供下式的化合物或其药学上可接受的盐,其中A是部分不饱和或不饱和的五元杂环或部分不饱和或不饱和的五元碳环,其中4-(磺酰基)苯基和4-取代的苯基 在式(I)中,与环A相邻的环原子相连; R 1是任选取代的芳基或杂芳基,条件是当A是吡唑时,R 1是杂芳基; R 2是C 1-4烷基,卤素取代的C 1-4烷基,C 1-4烷基氨基,C 1-4二烷基氨基或氨基; R 3,R 4和R 5独立地是氢,卤素,C 1-4烷基,卤素取代的C 1-4烷基等; 或R 3,R 4和R 5中的两个与它们所连接的原子一起形成4-7元环; R 6和R 7独立地是氢,卤素,C 1-4烷基,卤素取代的C 1-4烷基,C 1-4烷氧基,C 1-4烷硫基,C 1-4烷基氨基或N,N-二C1- 4烷基氨基; 并且m和n独立地为1,2,3或4.本发明还提供了可用于治疗前列腺素作为病原体的医学病症的药物组合物。
    • 3. 发明授权
    • Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
    • 磺酰苯化合物作为抗炎/止痛剂
    • US06608095B2
    • 2003-08-19
    • US09841348
    • 2001-04-24
    • Kazuo AndoTomoki KatoAkiyoshi KawaiTomomi Nonomura
    • Kazuo AndoTomoki KatoAkiyoshi KawaiTomomi Nonomura
    • A61K3141
    • C07D207/335C07D401/10C07D403/10C07D405/10C07D409/10C07D413/10C07D417/10
    • This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring; R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
    • 本发明提供下式的化合物或其药学上可接受的盐,其中A是部分不饱和或不饱和的五元杂环或部分不饱和或不饱和的五元碳环,其中4-(磺酰基)苯基和4-取代的苯基 在式(I)中,与环A相邻的环原子相连; R1是任选取代的芳基或杂芳基,条件是当A是吡唑时,R 1是杂芳基; R2是C1-4烷基,卤素取代的C1-4烷基,C1-4烷基氨基,C1-4二烷基氨基或氨基; R 3,R 4和R 5独立地为氢,卤素,C 1-4烷基,卤素取代的C 1-4烷基等; 或者R 3,R 4和R 5中的两个与它们所连接的原子一起形成4-7元环; R 6和R 7独立地是氢,卤素,C 1-4烷基,卤素取代的C 1-4烷基,C 1-4烷氧基,C 1-4烷硫基,C 1-4烷基氨基或N,N-二C 1-4烷基氨基; 并且m和n独立地为1,2,3或4.本发明还提供了可用于治疗前列腺素作为病原体的医学病症的药物组合物。
    • 6. 发明授权
    • Pyridylfuran and pyridylthiophene compounds
    • 吡啶基呋喃和吡啶基噻吩化合物
    • US6048880A
    • 2000-04-11
    • US3108
    • 1998-01-06
    • Akiyoshi KawaiMakoto Kawai
    • Akiyoshi KawaiMakoto Kawai
    • A61K31/44A61K31/443A61K31/4433A61K31/4436A61K31/4439A61K31/444A61K31/4545A61K31/496A61K31/5377A61P1/00A61P1/04A61P3/00A61P3/04A61P3/08A61P7/02A61P9/00A61P11/00A61P17/00A61P19/06A61P25/04A61P29/00A61P31/04A61P31/12A61P35/00A61P37/00A61P37/02A61P37/04A61P37/06A61P37/08A61P43/00C07D405/04C07D409/04C07D409/14C07D411/02C07D493/04C07D495/04C07D405/14
    • C07D405/04C07D409/04C07D409/14C07D493/04C07D495/04
    • A compound of the formula: ##STR1## and its pharmaceutically effective salts, wherein R.sup.1 and R.sup.2 are independently selected from the following:(a) hydrogen, halo, R.sup.5 --, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, hydroxy-R.sup.5 --, R.sup.5 --O--R.sup.5 --, or the like; (b) Ar--, Ar--R.sup.5 --, Ar--C.sub.2-6 alkenyl, Ar--C.sub.2-6 alkynyl, Ar--O--, Ar--O--R.sup.5 -- or the like; (c) R.sup.5 --C(O)--, --NO.sub.2, cyano, NH.sub.2 --C(O)--, R.sup.5 --NH--C(O)--, (R.sup.5).sub.2 --N--C(O)--, Ar--C(O)-- or the like; and (d) R.sup.5 --C(O)--NH--, Ar--C(O)--NH-- or the like; wherein Ar is optionally substituted aryl or heteroaryl such as phenyl and pyridyl; and wherein R.sup.5 is optionally halo-substituted C.sub.1-6 alkyl; R.sup.3 is selected from the following: (e) cyano, formyl, tetrazolyl, triazolyl, imidazolyl, oxazolyl, thiazolyl, R.sup.5 --C(O)--, C.sub.2-6 alkenyl-C(O)--, C.sub.2-6 alkynyl-C(O)--, R.sup.5 --C(O)--R.sup.5 --, or the like; (f) R.sup.5 --C(O)--NH--, Ar--C(O)--NH--, or the like; (g) R.sup.5 --S--, R.sup.5 --S(O)--, R.sup.5 --NH--S(O).sub.2 --, or the like; and (h) Ar--C(O)--, Ar--R.sup.5 --C(O)--, Ar--C.sub.2-6 alkenylene-C(O)-- or the like; or two of R.sup.1, R.sup.2 and R.sup.3 together form a group of the formula --A.sup.1 --B.sup.1 --A.sup.2 -- or --A.sup.1 --B.sup.1 --A.sup.3 --B.sup.2 --A.sup.2 -- such as cyclic alkyl optionally substituted with oxo; R.sup.4 is hydrogen, halo, R.sup.5 --C(O)-- and the like; X is O, S, S(O) or S(O).sub.2 ; m is 0, 1, 2, 3 or 4. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokine mediated diseases and/or cell adhesion molecule (CAM) mediated diseases and pharmaceutical compositions for use in such therapy.
    • 下式的化合物及其药学上有效的盐,其中R 1和R 2独立地选自以下:(a)氢,卤素,R 5 - ,C 2-6烯基,C 2-6炔基,羟基-R 5 - ,R 5 - O-R 5 - 等; (b)Ar-,Ar-R5-,Ar-C2-6烯基,Ar-C2-6炔基,Ar-O-,Ar-O-R5-等; (C)R 5 -C(O) - , - O 2,氰基,NH 2 -C(O) - ,R 5 -NH-C(O) - ,(R 5)2-NC(O) ) - 等等; 和(d)R 5 -C(O)-NH-,Ar-C(O)-NH-等; 其中Ar是任选取代的芳基或杂芳基,例如苯基和吡啶基; 并且其中R 5任选为卤素取代的C 1-6烷基; R3选自如下:(e)氰基,甲酰基,四唑基,三唑基,咪唑基,恶唑基,噻唑基,R5-C(O) - ,C2-6烯基-C(O) - ,C2-6炔基-C( O) - ,R 5 -C(O)-R 5 - 等; (f)R5-C(O)-NH-,Ar-C(O)-NH-等; (g)R5-S-,R5-S(O) - ,R5-NH-S(O)2 - 等; 和(h)Ar-C(O) - ,Ar-R 5 -C(O) - ,Ar-C 2-6亚烯基-C(O) - 等; 或两个R 1,R 2和R 3一起形成式-A1-B1-A2-或-A1-B1-A3-B2-A2-的基团,例如任选被氧代取代的环烷基; R4是氢,卤素,R5-C(O) - 等; X是O,S,S(O)或S(O)2; 本发明还提供其制备方法,其用于治疗细胞因子介导的疾病和/或细胞粘附分子(CAM)介导的疾病的用途和用于这种治疗的药物组合物 。
    • 8. 发明授权
    • Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
    • 磺酰苯化合物作为抗炎/止痛剂
    • US06949536B2
    • 2005-09-27
    • US10771861
    • 2004-02-03
    • Kazuo AndoTomoki KatoAkiyoshi KawaiTomomi Nonomura
    • Kazuo AndoTomoki KatoAkiyoshi KawaiTomomi Nonomura
    • A61K31/33A61K31/4025A61K31/422A61K31/425A61K31/427A61K31/454C07D233/00C07D277/00C07D333/00
    • A61K31/422A61K31/427A61K31/454C07C311/39C07C317/36C07D207/325C07D207/333C07D401/10C07D403/10C07D405/10C07D409/10C07D413/10C07D417/10
    • This invention provides a compound of the formula: or its pharmaceutically acceptable salt thereof, wherein A is partially unsaturated or unsaturated five membered heterocyclic, or partially unsaturated or unsaturated five membered carbocyclic, wherein the 4-(sulfonyl)phenyl and the 4-substituted phenyl in the formula (I) are attached to ring atoms of Ring A, which are adjacent to each other; R1 is optionally substituted aryl or heteroaryl, with the proviso that when A is pyrazole, R1 is heteroaryl; R2 is C1-4 alkyl; halo-substituted C1-4 alkyl, C1-4 alkylamino, C1-4 dialkylamino or amino; R3, R4 and R5 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl or the like; or two of R3, R4 and R5 are taken together with atoms to which they are attached and form a 4-7 membered ring. R6 and R7 are independently hydrogen, halo, C1-4 alkyl, halo-substituted C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino or N,N-di C1-4 alkylamino; and m and n are independently 1, 2, 3 or 4. This invention also provides a pharmaceutical composition useful for the treatment of a medical condition in which prostaglandins are implicated as pathogens.
    • 本发明提供下式的化合物或其药学上可接受的盐,其中A是部分不饱和或不饱和的五元杂环或部分不饱和或不饱和的五元碳环,其中4-(磺酰基)苯基和4-取代的苯基 在式(I)中,与环A相邻的环原子相连; R 1是任选取代的芳基或杂芳基,条件是当A是吡唑时,R 1是杂芳基; R 2是C 1-4烷基; 卤素取代的C 1-4烷基,C 1-4烷基氨基,C 1-4烷基氨基或氨基; R 4,R 4和R 5独立地是氢,卤素,C 1-4烷基,卤代 - 取代的C 1-4烷基等; 或者R 3,R 4和R 5中的两个与它们所连接的原子一起形成4-7元环 。 R 6和R 7独立地是氢,卤素,C 1-4烷基,卤素取代的C 1-4烷基, C 1-4烷基,C 1-4烷氧基,C 1-4烷硫基,C 1-4烷基氨基或N,N-二C < 烷基氨基; m和n分别为1,2,3或4.本发明还提供了一种药物组合物,其用于治疗前列腺素涉及病原体的医疗状况。